"id","name","label","studyInvestigationalInterventions","bcCategories","studyEstimands","uuid:ID","studyDesignRationale","description","documentVersion"
"StudyDesign_1","Study Design 1","","[]","[]","[]","7b998c1b-07cf-4b86-ad2a-f55403d1434f","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study",""
